Back to Search Start Over

Demonstration of In Vitro Host-Guest Complex Formation and Safety of para-Sulfonatocalix[8]arene as a Delivery Vehicle for Two Antibiotic Drugs.

Authors :
Moussa YE
Ong YQE
Perry JD
Cheng Z
Kayser V
Cruz E
Kim RR
Sciortino N
Wheate NJ
Source :
Journal of pharmaceutical sciences [J Pharm Sci] 2018 Dec; Vol. 107 (12), pp. 3105-3111. Date of Electronic Publication: 2018 Aug 27.
Publication Year :
2018

Abstract

The macrocycle para-sulfonatocalix[8]arene, sCX[8], was examined with 2 antibiotic drugs, ciprofloxacin (CIP) and isoniazid. The drugs were shown to form complexes with sCX[8] using proton nuclear magnetic resonance, thermogravimetric analysis, fluorescence spectroscopy, and molecular modeling. Both drugs form 1:1 hydrated (H <subscript>2</subscript> O: 13%-14% w/w) host-guest complexes, with sCX[8] binding around the pyridine ring of isoniazid, and around the piperazine and cyclopropane rings of CIP. From proton nuclear magnetic resonance, the binding constant of isoniazid to sCX[8] was 6.8 (±0.3) × 10 <superscript>3</superscript> M <superscript>-1</superscript> . Addition of 2 equivalents of sCX[8] to CIP resulted in a 58% decrease in fluorescence, and time-resolved fluorescence anisotropy of CIP doubles with sCX[8]. Each drug binds into the cavity of the macrocycle, with binding stabilized via combinations of hydrogen bonding, electrostatic interactions, π-π stacking, and hydrophobic effects. The safety of sCX[8] was examined in vitro with human embryonic kidney 293 cells. The IC <subscript>50</subscript> of sCX[8] was 559 μM, which is a minimum of 5-fold higher than the concentration that would be used in the clinic. The in vitro effect of sCX[8] on the action of CIP was examined on a panel of bacterial lines. The results showed that sCX[8] has no inherent antibiotic activity and had no negative effect on the action of CIP.<br /> (Copyright © 2018. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1520-6017
Volume :
107
Issue :
12
Database :
MEDLINE
Journal :
Journal of pharmaceutical sciences
Publication Type :
Academic Journal
Accession number :
30165066
Full Text :
https://doi.org/10.1016/j.xphs.2018.08.016